Dosing JAK Inhibitors in Patients With Myelofibrosis

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Related Content:

Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life

Key Takeaways for Patients With Myelofibrosis

Best Approaches to Switching Therapies for a Patient With Myelofibrosis

Assessing Treatment Response in Patients With Myelofibrosis